Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Back to Search
Print
Bookmark Trial

NCT00326326

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anniston, Alabama, 36207, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
30-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women

- Triglycerides between 150-500 mg/dL

- Fasting Plasma Glucose 140-240 mg/dL

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Known cardiovascular, carotid, or peripheral vascular disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

DyslipidemiaEffect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
NCT00326326
  1. Anniston, Alabama
  2. Huntsville, Alabama
  3. Greenbrae, California
  4. Los Angeles, California
  5. Walnut Creek, California
  6. DeFuniak Springs, Florida
  7. Destin, Florida
  8. Jupiter, Florida
  9. Melbourne, Florida
  10. Atlanta, Georgia
  11. Conyers, Georgia
  12. Chicago, Illinois
  13. Iowa City, Iowa
  14. Lexington, Kentucky
  15. Baltimore, Maryland
  16. Springfield, Missouri
  17. Omaha, Nebraska
  18. Las Vegas, Nevada
  19. Mount Vernon, New York
  20. Oklahoma City, Oklahoma
  21. Tulsa, Oklahoma
  22. Kingsport, Tennessee
  23. Bryan, Texas
  24. Houston, Texas
  25. San Antonio, Texas
  26. Newport News, Virginia
  27. Richmond, Virginia
  28. Richmond, Virginia
  29. Richmond, Virginia
  30. Yakima, Washington
  31. Milwaukee, Wisconsin
ALL GENDERS
30 Years+
years
MULTIPLE SITES
DyslipidemiaA Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.
NCT00708370
  1. Jitra, Kubang Pasu, Kedah
  2. Kulim, Kedah
  3. Sik, Kedah
  4. Kubang Kerian, Kelantan
  5. Cheras, Kuala Lumpur
  6. Cheras, Kuala Lumpur
  7. Nilai, Negeri Sembilan
  8. Tampin, Negeri Sembilan
  9. Bagan Serai, Perak
  10. Lenggong, Perak
  11. Slim River, Perak
  12. Kapar, Selangor
  13. Petaling Jaya, Selangor
  14. Puchong, Selangor
  15. Sungai Buloh, Selangor
  16. Kemaman, Terengganu
  17. Kerteh, Kemaman, Terengganu
  18. Kuala Lumpur, Wilayah Persekutuan
  19. Kuala Lumpur,
  20. Kuala Lumpur,
  21. Melaka,
  22. Shah Alam,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
DyslipidemiaObservational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
NCT00673660
  1. Mecidiyekoy, Istanbul
  2. Bolu,
  3. Haseki/Istanbul,
  4. Istanbul,
  5. Istanbul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
Official Title  ICMJE A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus
Brief Summary To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Dyslipidemia
Intervention  ICMJE Drug: CP-778,875
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: May 12, 2006)		84
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
  • Triglycerides between 150-500 mg/dL
  • Fasting Plasma Glucose 140-240 mg/dL

Exclusion Criteria:

  • Known cardiovascular, carotid, or peripheral vascular disease
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 30 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00326326
Other Study ID Numbers  ICMJE A5561005
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP